CV Sciences, Inc. acquired Elevated Softgels for $1.1 million.
May 13, 2024
Share
CV Sciences, Inc. (OTCPK:CVSI) entered into an agreement to acquire Elevated Softgels for $1.1 million on May 8, 2024.The consideration consists of $0.1 million in cash and $0.87 million through the issue of 15.9 million ordinary shares and $0.2 million in earnout related payments. The acquisition is expected to be accretive in its first year and contribute to scaling economics.
CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Elevated Softgels on May 13, 2024.
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. Its hemp extracts, and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business to business-to-consumer. It operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based therapeutics. It develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under brands: +PlusCBD and Cultured Foods in the healthcare market sector: nutraceutical, beauty care, specialty foods, and pet products. +PlusCBD branded products are sold at select retail locations throughout the United States. Cultured Foods brand provides a variety of plant-based food products and caters to individuals seeking vegan, gluten-free, or flexitarian options for a culinary experience. It manufactures encapsulated softgels and tinctures for the supplement and nutrition industry.
CV SCIENCES, INC. 
